Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
200
resultados
Última actualización
17/04/2026 [06:54:00]
Resultados 50 a 75 de 200
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: WO2018200943A1
Compounds are provided having one of the the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: MX2025011256A
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Resumen de: JP2026511197A
本発明は、少なくとも1つのゼオライトナノ結晶から成る、又は、少なくとも1つのゼオライトナノ結晶を含むナノ粒子を合成する方法であって、－アルミニウム供給源と、アルカリ金属Ｍ、とりわけＫのイオンの供給源とを含む、第一の組成物／溶液１が調製され；－ケイ素供給源と、アルカリ金属Ｍ、とりわけＫのイオンの供給源とを含む、第二の組成物／溶液２が調製され、ここで、前記組成物／溶液１及び２は、何らの有機構造化剤をも含まない；－前記２つの組成物／溶液１及び２が一緒に混合され；－前記混合物が結晶化され；かつ、－このようにして形成された前記ナノ粒子が分離されてよい方法に関する。本発明によれば、前記第一の組成物／溶液１及び前記第二の組成物／溶液２はいずれも、前記供給源及びリン酸緩衝生理食塩水から成る。本発明はまた、得られたナノ粒子のコロイド状懸濁液及び該ナノ粒子を含む医薬品組成物に関する。
Resumen de: CN120826370A
The invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal, comprising:-preparing a first composition/solution 1 comprising a source of aluminum and a source of ions of an alkali metal M, in particular of Na; preparing a second composition/solution 2 containing a source of silicon and a source of ions of an alkali metal M, in particular of Na, said compositions/solutions 1 and 2 being free of any organic structure directing agent; -mixing compositions/solutions 1 and 2 and placing the mixture under stirring; crystallizing the mixture at a temperature greater than or equal to 50 DEG C; and-optionally separating the formed nanoparticles. According to the invention, the first composition/solution 1 and the second composition/solution 2 each consist of said source and an alkaline phosphate buffer (PBS). The invention also relates to the nanoparticles thus obtained and to compositions containing these nanoparticles.
Resumen de: WO2024206076A1
The present disclosure pertains to biodegradable polymeric microspheres that comprise a biodegradable polymer and an immunotherapeutic agent selected from an inhibitor of poly ADP ribose polymerase enzyme (PARP inhibitor) and/or a Toll-like receptor (TLR) agonist wherein (a) 50% of a total amount of the immunotherapeutic agent in the biodegradable polymeric microspheres is released from the biodegradable polymeric microspheres into a 37°C solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; (b) between 1 mg and 100 mg of immunotherapeutic agent per 1 g dry weight of microspheres is released from the biodegradable polymeric microspheres into a 37°C solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; or (c) both (a) and (b). Other aspects of the present disclosure pertain to methods of using such microparticles and kits that contain such microparticles.
Resumen de: JP2026511099A
本明細書では、ＬＰＡ遺伝子におけるインビボ編集を達成することを対象とする遺伝子編集システム及び組成物が提供される。遺伝子編集によるアポ（ａ）産生の妨害及び血中リポタンパク質（ａ）［Ｌｐ（ａ）］濃度の低減による心血管疾患の治療又は予防が本明細書に開示される。ＬＰＡのコード配列における挿入及び／又は欠失（インデルバリアント）及び／又は非同義バリアントの導入を達成するように設計されたニッカーゼに基づく遺伝子編集システムが開示される。ニッカーゼに基づく遺伝子編集システムは一般に、１つ以上のニッカーゼと、複数のガイドオリゴヌクレオチド（例えば、ｇＲＮＡ）をコードする１つ以上のｍＲＮＡとを含み、それを必要とする哺乳動物対象に、潜在的に一回限りの治療として、（ＧａｌＮＡｃ標的化部分を有する、又は有さない）脂質ナノ粒子（ＬＮＰ）などの好適な送達システムを介して静脈内にインビボで送達され得るか、又は別の方法で投与され得る。遺伝子編集システム及び組成物の製造、使用、及び製剤化も開示される。
Resumen de: WO2024193827A1
The present disclosure relates generally to the field of stabilized compositions comprising particles dispersed in an aqueous phase, wherein the aqueous phase comprises a buffer system and has a pH of about 4.0-5.5 and wherein the particles contain (i) nucleic acid (such as DNA or RNA, in particular mRNA or inhibitory RNA, e.g., siRNA); and (ii) a cationic or cationically ionizable lipid, methods for preparing and storing such compositions, and the use of such compositions in therapy.
Resumen de: WO2024182676A2
The present disclosure provides antisense oligonucleotide compounds and compositions (e.g., pharmaceutical compositions) targeting NLRP3 and/or NLRP1 mRNA, and methods for treating diseases or conditions associated with NLRP3 and/or NLRP1 mRNA expression or NLRP3 and/or NLRP1 inflammasome activation. Exemplary conditions for which the compounds and compositions find use include inflammatory diseases such as neurodegenerative and autoimmune diseases, among others.
Resumen de: JP2026062827A
【課題】新規カチオン性脂質、治療剤の送達のための脂質ナノ粒子製剤の成分としての該化合物の使用、該化合物を含むナノ粒子、およびそれらの使用を提供する。【解決手段】下記の構造で示される化合物、またはその薬学的に許容される塩、互変異性体、または立体異性体が提供される。JPEG2026062827000031.jpg4868【選択図】なし
Resumen de: WO2021226108A1
Disclosed are pharmaceutical or cosmetic compositions comprising secretomes, for example secreted proteins from stem cells, and uses thereof. A composition that contains a secretome and an acceptable excipient may be free of a cell. The compositions are useful for inducing an immune response, treating an inflammatory response, treating a microbial infection, differentiating cells, wound healing, embryonic development, placental development, central nervous system development, or morphogenesis.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: WO2026075526A1
The present invention relates to a composition for treating psoriasis diseases using nano-graphene oxide. It was confirmed that the nano-graphene oxide of the present invention regulates inflammatory immune cell subtypes and tissue-resident memory cells, which are psoriasis-pathogenic immune cells. In addition, in an acute psoriasis animal model, it was confirmed that skin thickness, scaling, and erythema were reduced, and the thickness of the epidermal layer was decreased. Furthermore, it was confirmed that immune cells are regulated by reducing psoriasis-pathogenic immune cells and increasing immunoregulatory cells in splenocytes. Moreover, it was confirmed that mitochondrial functions are regulated by increasing mitochondrial ROS and oxygen consumption rates in psoriasis-pathogenic immune cells.
Resumen de: WO2026075516A1
The present invention relates to a polymer nanocomposite for brain-targeted drug delivery and a pharmaceutical composition comprising same. The polymer nanocomposite of the present invention has a structure in which (a) a cyclodextrin derivative bonded to a piperazine derivative, which is a brain-targeting ligand, and (b) a polymer chain bonded to a hydrophobic compound, which is a guest molecule, are self-assembled through host-guest interaction. The nanocomposite is loaded with a therapeutic drug and can efficiently penetrate the blood-brain barrier and deliver the drug to brain tissue through intranasal administration, which is a non-invasive route.
Resumen de: WO2026074471A1
Provide herein are methods of treating non-small cell lung cancer (NSCLC) in an individual in need thereof by administering a combination of a nanoparticle composition comprising HfO2, radiation therapy, chemotherapy, and a PD-L1 antibody to the individual. Also provided are methods of selecting an individual for treatment of NSCLC according to the methods provided herein.
Resumen de: WO2026076406A1
Compositions and methods for treating chlorine gas-induced pulmonary injury are disclosed. The described approach targets calcium/calmodulin-dependent protein kinase II (CaMKII), an enzyme activated in lung cells upon chlorine exposure, which contributes to oxidative stress and inflammation. The compositions include one or more CaMKII inhibitors, such as CaMKIIN peptides, encapsulated in liposomes and/or nanoparticles designed for pulmonary delivery. The liposomes can be conjugated with mitochondrial targeting moieties, such as triphenyl phosphonium bromide (TPP), to enhance delivery to mitochondria, where CaMKII activation occurs. The method involves administering the composition via inhalation or other routes to mitigate lung damage, reduce oxidative stress, and improve pulmonary function. This approach provides a targeted and effective solution for managing chlorine¬ induced respiratory distress, addressing limitations of current therapies.
Resumen de: US20260098014A1
Disclosed are lipidoid compounds having the structure of formula (I):or a salt thereof, wherein the groups are as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses pharmaceutical compositions comprising a lipidoid composition of the invention.
Resumen de: WO2026076268A1
The present invention relates to a system and method for generating and dispersing a mixture of nanoparticles and ions for neutralization of airborne pathogens in enclosed environments. A nebulizer introduces a salt precursor into a flame ionization stage, which produces a mixture of ions and nanoparticles at concentrations of at least 1.0 X 10^12 particles per cubic centimeter of air. The nanoparticles have an average size of less than 10 nanometers, and at approximately equal proportions with the ions. The systems and methods of the present invention reduce the pathogen viability by neutralization, inactivation, and agglomeration, and operate substantially free of ozone and, in alternate embodiments, include a two-duct alternating filtration arrangement for efficiency. Methods of testing include introducing pathogen surrogates into a chamber, generating the mixture of nanoparticles and ions by flame ionization, dispersing the mixture, and analyzing samples using aerosol and microbiological characterization techniques.
Resumen de: US20260097133A1
0000 The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.
Resumen de: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Nº publicación: AU2024351936A1 09/04/2026
Solicitante:
BATTELLE MEMORIAL INST
Resumen de: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
BOPI
Sede Electrónica
